
FDA Approves Giredestrant/Everolimus for ER+, HER2–, ESR1-Mutated Breast Cancer
The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated breast cancer based on data from the phase 3 evERA trial.
The FDA has approved giredestrant (Wilserdly), an oral selective estrogen receptor degrader (SERD), in combination with everolimus (Afinitor) as treatment for adults with estrogen receptor (ER)–positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease recurred during or after completion of endocrine-based adjuvant therapy, or has progressed on at least 1 endocrine-based regimen, according to a news release from the FDA.1
The FDA has also approved the FoundationOne Liquid CDx assay as a companion diagnostic to identify patients with breast cancer with ESR1 mutations for the newly approved treatment.
The regulatory decision was supported by findings from the phase 3 evERA Breast Cancer trial (NCT05306340), which randomly assigned patients 1:1 to receive giredestrant at 30 mg once daily (n = 183) or physician’s choice of endocrine therapy (n = 190). All patients also received once-daily everolimus at 10 mg.
Among patients with ESR1-mutant disease, the median PFS was 10 months (95% CI, 8.1-12.9) in the giredestrant plus everolimus arm vs 5.5 months (95% CI, 3.8-5.6) in the control arm (HR, 0.38; 95% CI, 0.27-0.54; P <.0001). The objective response rate (ORR) was 27% (95% CI, 18%-37%) vs 14% (95% CI, 8%-22%), respectively; the overall survival data were immature at the time of analysis.
In the trial, female patients who were pre- or peri-menopausal received a GnRH agonist for ovarian function suppression; male patients also received a GnRH, not including in cases of bilateral orchiectomy.
Regarding safety, the most common adverse events in the giredestrant plus everolimus arm were stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis, and nausea. The most common laboratory abnormalities included decreased hemoglobin, decreased lymphocytes, and decreased white blood cell count.
Per the approval information, the recommended dosage for oral giredestrant is 30 mg once daily with or without food until disease progression or unacceptable toxicity.
The warning label included warnings and precautions for bradycardia and embryo-fetal toxicity.
References
FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. News release. FDA. November 16, 2026. Accessed November 16, 2026. https://tinyurl.com/37ed7euf
Related to this article







